NETHERTON SYNDROME
Clinical trials for NETHERTON SYNDROME explained in plain language.
Never miss a new study
Get alerted when new NETHERTON SYNDROME trials appear
Sign up with your email to follow new studies for NETHERTON SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug for rare skin disease fails to reach goal
Disease control TerminatedThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Matched conditions: NETHERTON SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control TerminatedThis study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…
Matched conditions: NETHERTON SYNDROME
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Rare skin disease study seeks to understand netherton syndrome
Knowledge-focused TerminatedThis study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.
Matched conditions: NETHERTON SYNDROME
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC